AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32297162
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg/kg bolus over 30 minutes, followed by 1 mg/kg/h continuous infusion for 6 hours post-surgery)
Trial: 35089354
Drug: Antihypertensive medication
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive medication regimens that stimulate type 2 and 4 angiotensin II receptors
Trial: 35089354
Drug: Antihypertensive medication
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive medication regimens that inhibit type 2 and 4 angiotensin II receptors
Trial: 35089354
Drug: Stimulating-only antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulating-only antihypertensive medications
Trial: 35089354
Drug: Inhibiting-only antihypertensive
RxNorm normalized name: C1-inhibiting factor
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibiting-only antihypertensive medications
Trial: 32498113
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation empagliflozin tablet under fasting condition
Trial: 32498113
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation Jardiance under fasting condition
Trial: 32498113
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation empagliflozin tablet under fed condition
Trial: 32498113
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation Jardiance under fed condition
Trial: 34363293
Drug: Intrapartum oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrapartum oxytocin administration
Trial: 36114623
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (40 ppm) during DL,NO manoeuvre
Trial: 33559611
Drug: C‐phycocyanin (C‐PC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C‐phycocyanin (C‐PC) with small-molecule additives
Trial: 36231728
Drug: Bright Light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright Light Therapy (BLT) for 30 min/day for 4 weeks
Trial: 32639649
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of Metformin
Trial: 32579298
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) of rosuvastatin/metformin sustained-release (10/1000 mg) in fasted and fed states
Trial: 32579298
Drug: Separate tablets
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate tablets of 10 mg rosuvastatin and 1000 mg metformin sustained release in the fed state
Trial: 32579298
Drug: Effect of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effect of food on pharmacokinetics
Trial: 33971141
Drug: Apatinib 750
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 750 mg orally once daily
Trial: 33080623
Drug: Isatuximab monotherapy
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Isatuximab monotherapy (20 mg/kg on days 1, 8, 15, and 22 of cycle 1 followed by 20 mg/kg on days 1 and 15 of subsequent cycles)
Trial: 33080623
Drug: Isatuximab combined
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Isatuximab combined with dexamethasone (40 mg/d, 20 mg/d for patients aged ≥75 years, once weekly)
Trial: 36256584
Drug: Rapid maxillary
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid maxillary expansion (RME) activated twice daily
Trial: 32683790
Drug: l-citrulline (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-citrulline (3 g) daily for 2 months
Trial: 32683790
Drug: microcrystalline cellulose
RxNorm normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: microcrystalline cellulose (placebo) daily for 2 months
Trial: 32779919
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg prednisolone per day for 6 weeks
Trial: 34793405
Drug: Naltrexone (endogenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (endogenous opioid antagonist)
Trial: 32616263
Drug: 500 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/kg VC
Trial: 32616263
Drug: 1,000 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg/kg VC
Trial: 33451596
Drug: Placebo patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patches (hydrocolloid)
Trial: 33518471
Drug: Topical xylometazoline
RxNorm normalized name: XYLOMETAZOLINE
DrugBank: Xylometazoline (DB06694)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical xylometazoline (0.1%)
Trial: 33518471
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline nasal spray, 0.74% w/v isotonic solution)
Trial: 35346603
Drug: Bempedoic acid
RxNorm normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bempedoic acid + ezetimibe fixed-dose combination
Trial: 32379667
Drug: Routine care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine care and treatment (Control)
Trial: 34880010
Drug: 200 mL
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL convalescent plasma (CP) daily for up to 10 days (until virus negative in blood) plus standard care
Trial: 616497045
Drug: Eggshell calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eggshell calcium (300 mg/d)
Trial: 616497045
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (300 mg/d)
Trial: 33128303
Drug: Aspartame (ASP)
RxNorm normalized name: Aspartame
DrugBank: Aspartame (DB00168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (ASP) at a dose of 40 mg/kg/day
Trial: 33128303
Drug: Caffeine at
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine at a dose of 80 mg/kg/day
Trial: 33128303
Drug: Aspartame (ASP)
RxNorm normalized name: Aspartame
DrugBank: Aspartame (DB00168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (ASP) and caffeine combined at previous doses
Trial: 34015659
Drug: Sodium selenate
RxNorm normalized name: Sodium Selenate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium selenate (12.5 μg Se kg−1 soil)
Trial: 33118519
Drug: Medical ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical ozone oil (1 mL, applied locally 3 times per day for 12 weeks)
Trial: 33118519
Drug: Urea ointment
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea ointment (10% urea, 2 g, applied locally 3 times per day for 12 weeks)
Trial: 34011342
Drug: Preoperative LMWH
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative LMWH administration (4000 IU per day)
Trial: 34011342
Drug: Postoperative LMWH
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative LMWH administration (4000 IU per day)
Trial: 32147037
Drug: High-Intensity Laser
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Laser Therapy (HILT) plus exercise
Trial: 32147037
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Ultrasound (US), Transcutaneous Nerve Stimulation (TENS) and exercise
Trial: 33015809
Drug: Propofol administration
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol administration (MED)
Trial: 33781915
Drug: Pabinafusp alfa
RxNorm normalized name: Pabinafusp alfa
DrugBank: Pabinafusp alfa (DB15633)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Pabinafusp alfa at 1.0 mg/kg/week
Trial: 33781915
Drug: Pabinafusp alfa
RxNorm normalized name: Pabinafusp alfa
DrugBank: Pabinafusp alfa (DB15633)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Pabinafusp alfa at 2.0 mg/kg/week
Trial: 33781915
Drug: Pabinafusp alfa
RxNorm normalized name: Pabinafusp alfa
DrugBank: Pabinafusp alfa (DB15633)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Pabinafusp alfa at 4.0 mg/kg/week
Trial: 33343577
Drug: Quadrivalent inactivated
RxNorm normalized name: Fluarix Quadrivalent 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent inactivated influenza vaccines (QIVs)
Trial: 35361657
Drug: Single pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single pill containing quadruple combination of quarter doses of blood pressure medicines
Trial: 35361657
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose irbesartan
Trial: 33124749
Drug: Caffeine intake
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine intake of 180 mg shortly before surgery (intervention group)
Trial: 36402670
Drug: Volanesorsen 300
RxNorm normalized name: Volanesorsen
DrugBank: Volanesorsen (DB15067)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Volanesorsen 300 mg weekly subcutaneous injection
Trial: 33052103
Drug: Two‐compound gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two‐compound gel once daily for 28 weeks
Trial: 33052103
Drug: Calcipotriol scalp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol scalp solution twice daily for 28 weeks
Trial: 36478762
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of direct oral anticoagulants (DOAC) within 48 hours of minor or moderate stroke, or at day 6-7 following major stroke.
Trial: 36478762
Drug: Late initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Late initiation of direct oral anticoagulants (DOAC) after day 3-4 following minor stroke, after day 6-7 following moderate stroke and after day 12-14 following major stroke.
Trial: 36478762
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of direct oral anticoagulants (DOAC)
Trial: 36478762
Drug: Late initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Late initiation of direct oral anticoagulants (DOAC)
Trial: 34023312
Drug: 1-step diagnostic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-step diagnostic testing protocol (75 g, 2-hour oral glucose tolerance test)
Trial: 34023312
Drug: 2-step screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-step screening protocol (50 g, 1-hour glucose challenge followed by 100 g, 3-hour oral glucose tolerance test)
Trial: 32020414
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus two HIIT sessions (MET+EX)
Trial: 34721385
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) in addition to pharmacotherapy (SLIT+PT)
Trial: 34721385
Drug: Pharmacotherapy (PT)
RxNorm normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy (PT) alone
Trial: 35213393
Drug: Green Tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green Tea Extract (GTE) standardized to 150 mg of EGCG b.i.d. for 3 years
Trial: 32014060
Drug: Intratympanic methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic methylprednisolone (4 doses of 1 mL of 40 mg/mL over 1 week, every 2 days)
Trial: 32014060
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (1 mg/kg/day, maximal dose 60 mg/day for 5 days)
Trial: 35673509
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa (N.S) oil supplement, 2000 mg/d for 8 weeks
Trial: 32191366
Drug: Psychoeducational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychoeducational intervention (adequate dose participants)
Trial: 32191366
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (adequate dose participants)
Trial: 32926410
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy (NPWT) and Control group
Trial: 33305900
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine (0.3 mg/kg)
Trial: 35502922
Drug: Fostemsavir plus
RxNorm normalized name: fostemsavir
DrugBank: Fostemsavir (DB11796)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostemsavir plus optimized background therapy (OBT)
Trial: 35502922
Drug: Optimized background
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized background therapy (OBT)
Trial: 35694933
Drug: Mevidalen (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mevidalen (30 mg)
Trial: 35694933
Drug: Mevidalen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mevidalen (10 mg)
Trial: 34664427
Drug: Mevidalen (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mevidalen (75 mg)
Trial: 33674869
Drug: Targeted azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Targeted azithromycin treatment (thrice over the following year)
Trial: 33674869
Drug: Delayed azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Delayed azithromycin treatment
Trial: 33674869
Drug: Targeted azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Targeted azithromycin treatment
Trial: 35452830
Drug: CRRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRRT with topical citrate + low-dose LMW heparin-calcium anticoagulation
Trial: 35452830
Drug: CRRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRRT with low molecular weight (LMW) heparin-calcium anticoagulation
Trial: 35775311
Drug: Adjunctive diode
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive diode laser application (90s, 810nm, 2.5W, 50Hz, 10ms)
Trial: 35775311
Drug: Non-activated adjunctive
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-activated adjunctive diode laser
Trial: 35775311
Drug: Adjunctive diode
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive diode laser application
Trial: 33137378
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone (PIO) 15 mg daily for 6 months
Trial: 33957651
Drug: Mifepristone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (200 mg oral, 36 hours before surgery)
Trial: 33957651
Drug: Misoprostol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (400 micrograms buccal, 3 hours before surgery)
Trial: 32525882
Drug: Care bundle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Care bundle interventions including chest X-ray, CURB-65 severity score, lower respiratory tract samples, and antibiotics within 8 hours from admission.
Trial: 36115950
Drug: 80 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/d of iron (Stratum 1)
Trial: 36115950
Drug: 40 mg/d
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/d of iron (Stratum 1)
Trial: 36115950
Drug: 40 mg/d
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/d of iron (Stratum 2)
Trial: 36115950
Drug: 20 mg/d
RxNorm normalized name: Valtoco, 20 mg/dose nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/d of iron (Stratum 2)
Trial: 34710557
Drug: Difamilast ointment
RxNorm normalized name: Difamilast
DrugBank: Difamilast (DB14987)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Difamilast ointment 1%
Trial: 32890575
Drug: 300 IR
RxNorm normalized name: ORALAIR 300 IR TAB,SL PKT 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 IR sublingual tablet
Trial: 35668500
Drug: Curcumin-piperine co-supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin-piperine co-supplementation (500 mg curcumin + 5 mg piperine, 2 capsules daily for 14 days)
Trial: 35668500
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 capsules daily for 14 days)
Trial: 34996756
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg orally once daily for 30 days
Trial: 32678954
Drug: Non-surgical debridement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical debridement and glycine powder (G)
Trial: 35191210
Drug: Isavuconazonium sulfate
RxNorm normalized name: Isavuconazonium Sulfate
DrugBank: Isavuconazonium (DB06636)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Isavuconazonium sulfate (200 mg equivalent of isavuconazole) administered orally or intravenously once daily for 16 days with a loading regimen every 8 hours for the first 48 hours
Trial: 35191210
Drug: Isavuconazonium sulfate
RxNorm normalized name: Isavuconazonium Sulfate
DrugBank: Isavuconazonium (DB06636)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Isavuconazonium sulfate (100 mg, 200 mg, and 400 mg equivalent of isavuconazole) administered orally or intravenously (single ascending dose)
Trial: 33238198
Drug: aPDT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aPDT + oral hygiene behavior (OHB)
Trial: 33238198
Drug: Lingual scraper
RxNorm normalized name: Nitroglycerin Lingual Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lingual scraper + oral hygiene behavior (OHB)
Trial: 33552050
Drug: Novel non-replacement
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel non-replacement therapies (including emicizumab)
Trial: 36178679
Drug: Twice-weekly membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly membrane sweeping
Trial: 36178679
Drug: Once-weekly membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly membrane sweeping
Trial: 37042545
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg zolmitriptan
Trial: 32162796
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oncologist training and patient communication aid
Trial: 34463409
Drug: Empagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (10 mg, 25 mg)
Trial: 32028395
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment and antimicrobial photodynamic therapy (PACT)
Trial: 33104452
Drug: Voice bubbling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice bubbling therapy (VBT)
Trial: 34634254
Drug: Single-dose HPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose HPV vaccine
Trial: 34634254
Drug: Two-dose HPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose HPV vaccine
Trial: 34634254
Drug: Three-dose HPV
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dose HPV vaccine
Trial: 32739466
Drug: Citalopram 20
RxNorm normalized name: citalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 20 mg/d plus 5 mL placebo syrup every 12 h
Trial: 32739466
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of lavender-dodder herbal syrup every 12 h plus placebo tablets once daily
Trial: 35729519
Drug: Ethinyl Estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinyl Estradiol (EE) starting at 11 years old with Growth Hormone (GH)
Trial: 35729519
Drug: Ethinyl Estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinyl Estradiol (EE) starting at 13 years old with Growth Hormone (GH)
Trial: 35729519
Drug: Ethinyl Estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinyl Estradiol (EE) therapy